Alphamab Oncology (HKG:9966)
Hong Kong · Delayed Price · Currency is HKD 7.85
+0.06 (0.77%)
Mar 6, 2026, 4:08 PM HKT
Alphamab Oncology Market Cap
Alphamab Oncology has a market cap or net worth of 7.6 billion as of March 6, 2026. Its market cap has increased by 111.25% in one year.
Market Cap
7.60B
Enterprise Value
6.10B
Revenue
861.24M
Ranking
n/a
PE Ratio
30.32
Stock Price
7.85
Market Cap Chart
Since December 12, 2019, Alphamab Oncology's market cap has decreased from 12.11B to 7.60B, a decrease of -37.21%. That is a compound annual growth rate of -7.19%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 7.60B | -19.90% |
| Dec 31, 2025 | 9.49B | 181.80% |
| Dec 31, 2024 | 3.37B | -47.42% |
| Dec 29, 2023 | 6.41B | -36.87% |
| Dec 30, 2022 | 10.15B | -20.36% |
| Dec 31, 2021 | 12.74B | -16.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 12, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Guangzhou Innogen Pharmaceutical Group | 10.39B |
| Nanjing Leads Biolabs | 10.27B |
| Shanghai Haohai Biological Technology | 9.86B |
| HBM Holdings | 9.76B |
| CStone Pharmaceuticals | 8.69B |
| Abbisko Cayman | 7.62B |
| CK Life Sciences Int'l., (Holdings) | 7.59B |
| Lepu Biopharma | 7.52B |